Torasemide and zofenopril in acutely decompensated chronic heart failure – practice in Warsaw Case report
Article Sidebar
Main Article Content
Abstract
Guidelines of European Society of Cardiology for management of acute and chronic heart failure recommend intravenous loop diuretics in all patients with acute heart failure and signs of fluid overload in order to improve symptoms. Loop diuretics available in Poland – furosemide and torasemide – have similar therapeutic effect, but differ in a variety of features. In the following article relevant differences have been presented along with examples of torasemide administration in acute decompensation of chronic heart failure. Furthermore, the guidelines recommend administering angiotensin converting enzyme inhibitors in all patients with symptomatic heart failure with reduced ejection fraction due to proven reduction in mortality and morbidity. The paper presents advantages of zofenopril.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Charakterystyka produktu leczniczego: Furosemidum Polpharma 10 mg/ml, roztwór do wstrzykiwań; 17.12.2015.
3. Charakterystyka produktu leczniczego: Trifas 10, 20; 5 mg/ml, roztwór do wstrzykiwań; 2.05.2014.
4. Filipiak K.J. (red.): Torasemid. Biblioteka czasopisma Cardiology Journal 2011, tom 14.
5. Cosin J., Diez J.; TORIC investigators: Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 2002; 4: 507-513.
6. Lopez B., Gonzalez A., Beaumont J. et al.: Identification of potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007; 50: 859-867.
7. Müller K., Gamba G., Jaquet F. et al.: Torasemide vs furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur. J. Heart Fail. 2003; 5: 793-801.
8. Bolke T., Achhammer I.: Torasemide: review of its pharmacology and therapeutic use. Drugs of Today 1994; 30(8): 1-26.
9. Ambrosioni E., Borghi C., Magnani B.: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. 1995; 332(2): 80-85.
10. Borghi C., Ambrosioni E., Novo S. et al.: Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE- 4). Clin. Cardiol. 2012; 35: 416-423.